OncoMatch/Clinical Trials/NCT06465316
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Is NCT06465316 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Iberdomide and Teclistamab for recurrent multiple myeloma.
Treatment: Iberdomide · Teclistamab — This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving iberdomide in combination with teclistamab may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor (bortezomib, carfilzomib, ixazomib)
Patients must have had disease progression after ≥ 4 prior lines of anti-myeloma treatments including one proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib)
Must have received: immunomodulatory imide drug (thalidomide, lenalidomide, pomalidomide)
Patients must have had disease progression after ≥ 4 prior lines of anti-myeloma treatments including one immunomodulatory imide drug (ImiD) (e.g., thalidomide, lenalidomide, pomalidomide [POM])
Must have received: anti-CD38 monoclonal antibody (daratumumab, isatuximab)
Patients must have had disease progression after ≥ 4 prior lines of anti-myeloma treatments including one anti-CD38 monoclonal antibody (e.g., daratumumab, isatuximab)
Cannot have received: anti-BCMA directed bispecific antibody
Patients who have had prior anti-BCMA directed bispecific antibody (BsAb) therapy exposure
Cannot have received: cereblon E3 ligase modulator (mezigdomide, iberdomide, CFT7455)
Patients who have had prior treatment with a cereblon E3 ligase modulator, including mezigdomide, iberdomide, and CFT7455
Cannot have received: allogeneic stem cell transplant
Patients who received a prior allogeneic stem cell transplant. Autologous SCT is allowed
Lab requirements
Blood counts
Hemoglobin ≥ 7.0 g/dL (without growth factor support, blood transfusion, or platelet stimulating agents for the past 7 days, excluding erythropoietin); Absolute neutrophil count ≥ 1,000/mcL; Platelets ≥ 50,000/mcL
Kidney function
Estimated glomerular filtration rate (eGFR) > 30 mL/min; Spot urine (albumin/creatine ratio) ≤ 500mg/g OR urine dipstick negative/trace (if > 1+ only eligible if confirmed ≤ 500 mg/g by albumin/creatinine ratio)
Liver function
Total bilirubin ≤ 2 x institutional upper limit of normal (ULN); AST/ALT ≤ 3 x institutional ULN
Cardiac function
NYHA class II or better if cardiac disease or prior cardiotoxic therapy
Hemoglobin ≥ 7.0 g/dL... Absolute neutrophil count ≥ 1,000/mcL... Platelets ≥ 50,000/mcL... Total bilirubin ≤ 2 x institutional upper limit of normal (ULN)... AST/ALT ≤ 3 x institutional ULN... eGFR > 30 mL/min... Spot urine (albumin/creatine ratio) ≤ 500mg/g OR urine dipstick negative/trace... NYHA class II or better if cardiac disease or prior cardiotoxic therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Hospital in Arizona · Phoenix, Arizona
- Smilow Cancer Hospital-Derby Care Center · Derby, Connecticut
- Smilow Cancer Hospital Care Center - Guilford · Guilford, Connecticut
- Yale University · New Haven, Connecticut
- Yale-New Haven Hospital North Haven Medical Center · North Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify